O	0	5	Phase
O	6	9	III
O	10	16	double
O	16	17	-
O	17	22	blind
O	22	23	,
O	24	31	placebo
O	31	32	-
O	32	42	controlled
O	42	43	,
O	44	55	prospective
O	56	66	randomized
O	67	72	trial
O	73	75	of
O	76	84	adjuvant
B-intervention	85	94	tamoxifen
O	95	97	vs
O	97	98	.
B-control	99	108	tamoxifen
I-control	109	112	and
I-control	113	124	fenretinide
O	125	127	in
O	128	142	postmenopausal
O	143	148	women
O	149	153	with
O	154	162	positive
O	163	172	receptors
O	173	174	(
O	174	179	EB193
O	179	180	)
O	180	181	:
O	182	184	an
O	185	195	intergroup
O	196	201	trial
O	202	213	coordinated
O	214	216	by
O	217	220	the
O	221	228	Eastern
O	229	240	Cooperative
O	241	249	Oncology
O	250	255	Group
O	255	256	.

O	257	268	Fenretinide
O	269	272	and
O	273	282	tamoxifen
O	283	287	have
O	288	296	additive
O	297	306	antitumor
O	307	314	effects
O	315	328	preclinically
O	328	329	.

O	330	332	We
O	333	342	performed
O	343	344	a
O	345	355	randomized
O	355	356	,
O	357	364	placebo
O	364	365	-
O	365	375	controlled
O	375	376	,
O	377	383	double
O	383	384	-
O	384	389	blind
O	390	398	adjuvant
O	399	404	trial
O	405	407	in
O	408	414	breast
O	415	421	cancer
O	422	430	patients
O	431	438	treated
O	439	442	for
O	443	444	5
O	445	450	years
O	451	455	with
O	456	465	tamoxifen
O	465	466	,
O	467	471	with
O	472	474	or
O	475	482	without
O	483	494	fenretinide
O	494	495	.

O	496	503	Between
O	504	511	October
O	512	516	1995
O	517	520	and
O	521	528	October
O	529	533	1999
O	533	534	,
B-total-participants	535	538	426
B-eligibility	539	553	postmenopausal
I-eligibility	554	559	women
I-eligibility	560	564	with
I-eligibility	565	572	hormone
I-eligibility	573	581	receptor
I-eligibility	581	582	-
I-eligibility	582	590	positive
I-eligibility	591	597	breast
I-eligibility	598	604	cancer
O	605	609	were
O	610	620	randomized
O	620	621	.

O	622	630	Patients
O	631	635	were
O	636	645	monitored
O	646	649	for
O	650	658	efficacy
O	659	662	and
O	663	671	toxicity
O	671	672	.

B-total-participants	673	677	Four
I-total-participants	678	685	hundred
I-total-participants	686	689	and
I-total-participants	690	698	nineteen
O	699	707	patients
O	708	712	were
O	713	722	evaluable
O	722	723	.

O	724	727	The
O	728	733	study
O	734	737	was
O	738	748	terminated
O	749	754	early
O	755	758	due
O	759	761	to
O	762	766	slow
O	767	774	accrual
O	774	775	.

O	776	781	There
O	782	786	were
O	787	789	no
O	790	801	significant
O	802	813	differences
O	814	821	between
O	822	831	treatment
O	832	838	groups
O	839	841	in
B-outcome	842	845	DFS
I-outcome	845	846	,
I-outcome	847	850	TTR
I-outcome	851	853	or
I-outcome	854	862	survival
O	862	863	.

O	864	868	More
O	869	877	patients
B-outcome	878	885	stopped
I-outcome	886	895	treatment
O	896	901	early
O	902	904	on
O	905	908	the
O	909	920	fenretinide
O	921	924	arm
O	925	929	than
O	930	932	on
O	933	940	placebo
O	941	942	(
O	942	943	P
O	944	945	=
O	946	947	0
O	947	948	.
O	948	950	02
O	950	951	)
O	951	952	.

B-outcome	953	958	Grade
I-outcome	959	960	3
I-outcome	960	961	/
I-outcome	961	962	4
I-outcome	963	973	toxicities
O	973	974	,
O	975	984	including
B-outcome	985	991	visual
I-outcome	992	1000	problems
O	1001	1004	and
B-outcome	1005	1020	musculoskeletal
I-outcome	1021	1031	complaints
O	1032	1036	were
O	1037	1041	more
O	1042	1048	common
O	1049	1051	in
O	1052	1060	patients
O	1061	1070	receiving
O	1071	1082	fenretinide
O	1083	1084	(
O	1084	1085	P
O	1086	1087	=
O	1088	1089	0
O	1089	1090	.
O	1090	1093	007
O	1093	1094	)
O	1094	1095	.

O	1096	1097	A
O	1098	1103	Night
O	1104	1113	Blindness
O	1114	1127	Questionnaire
O	1128	1131	was
O	1132	1136	used
O	1137	1139	to
O	1140	1147	monitor
O	1148	1158	nyctalopia
O	1158	1159	,
O	1160	1165	which
O	1166	1169	was
O	1170	1178	slightly
O	1178	1179	,
O	1180	1183	but
O	1184	1187	not
O	1188	1201	significantly
O	1201	1202	,
O	1203	1207	more
O	1208	1214	common
O	1215	1217	on
O	1218	1229	fenretinide
O	1229	1230	.

O	1231	1233	In
O	1234	1238	this
O	1239	1251	underpowered
O	1252	1257	study
O	1257	1258	,
O	1259	1261	no
O	1262	1273	significant
O	1274	1284	difference
O	1285	1288	was
O	1289	1297	observed
O	1298	1300	in
O	1301	1309	efficacy
O	1310	1317	between
O	1318	1327	treatment
O	1328	1334	groups
O	1334	1335	.

O	1336	1340	This
O	1341	1346	trial
O	1347	1355	provides
O	1356	1365	important
O	1366	1374	toxicity
O	1375	1386	information
O	1387	1392	about
O	1393	1404	fenretinide
O	1404	1405	,
O	1406	1407	a
O	1408	1416	retinoid
O	1417	1421	that
O	1422	1425	has
O	1426	1430	been
O	1431	1435	used
O	1436	1438	in
O	1439	1442	the
O	1443	1453	prevention
O	1454	1461	setting
O	1461	1462	,
O	1463	1470	because
O	1471	1473	it
O	1474	1476	is
O	1477	1480	the
O	1481	1485	only
O	1486	1493	placebo
O	1493	1494	-
O	1494	1504	controlled
O	1504	1505	,
O	1506	1512	double
O	1512	1513	-
O	1513	1518	blind
O	1519	1529	randomized
O	1530	1535	study
O	1536	1540	ever
O	1541	1550	performed
O	1550	1551	.
